Recent Finacing
Recent Raise
Esperas Pharma is a Montréal-based special-purpose company developing ESP-001, an oral Chk1 inhibitor, conducting dose-escalation and proof-of-concept trials across HGSOC, pancreatic cancer, TNBC, and genetically selected cohorts.
Recent Investors
Funding rounds
Investors